These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19109739)

  • 1. Antiinflammatory effects of etoricoxib alone and combined with NSAIDs in LPS-induced reactive arthritis.
    Bressan E; Tonussi CR
    Inflamm Res; 2008 Dec; 57(12):586-92. PubMed ID: 19109739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of TNFalpha, IL-1beta and CINC-1 for articular incapacitation, edema and cell migration in a model of LPS-induced reactive arthritis.
    Bressan E; Cunha Fde Q; Tonussi CR
    Cytokine; 2006 Oct; 36(1-2):83-9. PubMed ID: 17166735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of etoricoxib and indomethacin for the treatment of experimental periodontitis in rats.
    Azoubel MC; Menezes AM; Bezerra D; Oriá RB; Ribeiro RA; Brito GA
    Braz J Med Biol Res; 2007 Jan; 40(1):117-25. PubMed ID: 17225004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
    Dallob A; Hawkey CJ; Greenberg H; Wight N; De Schepper P; Waldman S; Wong P; DeTora L; Gertz B; Agrawal N; Wagner J; Gottesdiener K
    J Clin Pharmacol; 2003 Jun; 43(6):573-85. PubMed ID: 12817520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
    Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret JP; Friesen RW; Gordon R; Greig G; Guay J; Mancini J; Ouellet M; Wong E; Xu L; Boyce S; Visco D; Girard Y; Prasit P; Zamboni R; Rodger IW; Gresser M; Ford-Hutchinson AW; Young RN; Chan CC
    J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
    Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory and analgesic actions of etoricoxib (an NSAID) combined with misoprostol.
    Moraes BM; do Amaral BC; Morimoto MS; Vieira LG; Perazzo FF; Carvalho JC
    Inflammopharmacology; 2007 Aug; 15(4):175-8. PubMed ID: 17701021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP; Curtis SP; Bolognese JA; Laine L;
    Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LPS-induced knee-joint reactive arthritis and spinal cord glial activation were reduced after intrathecal thalidomide injection in rats.
    Bressan E; Mitkovski M; Tonussi CR
    Life Sci; 2010 Oct; 87(15-16):481-9. PubMed ID: 20837031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
    Matsumoto AK; Melian A; Mandel DR; McIlwain HH; Borenstein D; Zhao PL; Lines CR; Gertz BJ; Curtis S;
    J Rheumatol; 2002 Aug; 29(8):1623-30. PubMed ID: 12180720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent analgesic and anti-inflammatory activities of 1-furan-2-yl-3-pyridin-2-yl-propenone with gastric ulcer sparing effect.
    Lee ES; Park BC; Paek SH; Lee YS; Basnet A; Jin DQ; Choi HG; Yong CS; Kim JA
    Biol Pharm Bull; 2006 Feb; 29(2):361-4. PubMed ID: 16462046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses.
    Takeuchi K; Suzuki K; Yamamoto H; Araki H; Mizoguchi H; Ukawa H
    J Physiol Pharmacol; 1998 Dec; 49(4):501-13. PubMed ID: 10069692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of Mycobacterium tuberculosis-induced monoarticular arthritis in the rat.
    Gilroy DW; Tomlinson A; Greenslade K; Seed MP; Willoughby DA
    Inflammation; 1998 Oct; 22(5):509-19. PubMed ID: 9793797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
    Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
    Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout.
    Navarra S; Rubin BR; Yu Q; Smugar SS; Tershakovec AM
    Curr Med Res Opin; 2007 Jul; 23(7):1685-91. PubMed ID: 17588299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation.
    Wallace JL; Chapman K; McKnight W
    Br J Pharmacol; 1999 Mar; 126(5):1200-4. PubMed ID: 10205009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
    Jaworek J; Bonior J; Tomaszewska R; Jachimczak B; Kot M; Bielański W; Pawlik WW; Sendur R; Stachura J; Konturek PC; Konturek SJ
    J Physiol Pharmacol; 2001 Mar; 52(1):107-26. PubMed ID: 11321505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model.
    Horizoe T; Nagakura N; Chiba K; Shirota H; Shinoda M; Kobayashi N; Numata H; Okamoto Y; Kobayashi S
    Inflamm Res; 1998 Oct; 47(10):375-83. PubMed ID: 9831321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.